Information  X 
Enter a valid email address

Company Name matching 'Oxurion NV'

Date
Time Source
Company
Announcement
29 Jul 2022 6:00 pm GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
11 Jul 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
30 Jun 2022 7:00 pm GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds
13 Jun 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
07 Jun 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
03 Jun 2022 7:00 am GNW   Oxurion NV Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
01 Jun 2022 6:15 pm GNW   Oxurion NV Oxurion to Participate in Upcoming Investor Conferences
31 May 2022 6:00 pm GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
25 May 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022
24 May 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
09 May 2022 7:30 am GNW   Oxurion NV Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)
06 May 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022
05 May 2022 6:00 pm GNW   Oxurion NV Oxurion to Participate in Upcoming Conferences
03 May 2022 6:10 pm GNW   Oxurion NV Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting  
29 Apr 2022 6:00 pm GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
11 Apr 2022 6:00 am GNW   Oxurion NV Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01 Apr 2022 6:00 pm GNW   Oxurion NV Oxurion Announces Extraordinary and Annual Shareholders’ Meetings
30 Mar 2022 6:00 pm GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA
28 Mar 2022 7:00 am GNW   Oxurion NV Oxurion to Participate in Needham Virtual Healthcare Conference
25 Mar 2022 9:11 pm GNW   Oxurion NV Oxurion Publishes 2021 Annual Report
17 Mar 2022 6:00 pm GNW   Oxurion NV Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG
07 Mar 2022 9:00 am GNW   Oxurion NV Oxurion Successfully Closes EUR >10 Million in Private Placement
03 Mar 2022 11:15 am GNW   Oxurion NV OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT
  7:00 am GNW   Oxurion NV OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT
22 Feb 2022 7:01 am GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
  7:00 am GNW   Oxurion NV Oxurion NV announces 2021 Full Year Results and 2022 Outlook
14 Feb 2022 7:00 am GNW   Oxurion NV Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference
11 Feb 2022 7:00 am GNW   Oxurion NV Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
08 Feb 2022 7:00 am GNW   Oxurion NV Oxurion to Participate in the 2022 BIO CEO and Investor Conference
18 Jan 2022 7:00 am GNW   Oxurion NV OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
07 Jan 2022 6:00 am GNW   Oxurion NV Oxurion Provides Update on Clinical Pipeline Progress
04 Jan 2022 5:00 pm GNW   Oxurion NV OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
30 Nov 2021 6:00 am GNW   Oxurion NV Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
24 Nov 2021 6:30 am GNW   Oxurion NV OXURION to Present at the Ophthalmology Day at BTIG
22 Nov 2021 6:00 am GNW   Oxurion NV OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures
15 Nov 2021 6:00 am GNW   Oxurion NV OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)
04 Nov 2021 6:00 am GNW   Oxurion NV Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation
13 Oct 2021 6:00 am GNW   Oxurion NV Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
11 Oct 2021 6:00 am GNW   Oxurion NV OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists (ASRS) Annual Scientific Meeting
30 Sep 2021 6:00 am GNW   Oxurion NV OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
09 Sep 2021 6:00 pm GNW   Oxurion NV Oxurion NV Business & Financial Update – H1 2021
17 Aug 2021 7:00 am GNW   Oxurion NV Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal
16 Aug 2021 7:00 am GNW   Oxurion NV Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149
05 Aug 2021 4:45 pm GNW   Oxurion NV OXURION to Participate in Upcoming Investor Meetings
25 Jun 2021 6:00 am GNW   Oxurion NV Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
10 Jun 2021 6:00 am GNW   Oxurion NV OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
08 Jun 2021 6:00 am GNW   Oxurion NV OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
17 May 2021 6:30 am GNW   Oxurion NV OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
30 Apr 2021 6:30 am GNW   Oxurion NV OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting
13 Apr 2021 6:30 am GNW   Oxurion NV OXURION NV to Present at Wet AMD and DME Drug Development Summit
12 Apr 2021 6:30 am GNW   Oxurion NV Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting
09 Apr 2021 6:38 am GNW   Oxurion NV ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
07 Apr 2021 4:45 pm GNW   Oxurion NV Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
06 Apr 2021 6:30 am GNW   Oxurion NV Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
31 Mar 2021 6:30 am GNW   Oxurion NV OXURION to Participate in Upcoming Investor Meetings
17 Mar 2021 7:00 pm GNW Factsheet Oxurion NV (0G99) Oxurion NV Business and Financial Update – FY 2020
08 Mar 2021 7:00 am GNW Factsheet Oxurion NV (0G99) OXURION to Participate in Upcoming Investor Meetings
20 Jan 2021 7:00 am GNW Factsheet Oxurion NV (0G99) Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
07 Jan 2021 7:00 am GNW Factsheet Oxurion NV (0G99) OXURION to Participate in Upcoming Investor Meetings
09 Nov 2020 6:30 am GNW Factsheet Oxurion NV (0G99) OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices


Company Announcements Archive »


a d v e r t i s e m e n t